EUVIMEDEUVIMED entdecken
Crossref

Discovery of SH-17 as a pioneering STAT3/HDAC bifunctional inhibitor that simultaneously impairs Tyr705 and Ser727 phosphorylation

Yulei Liu, Xiuxiu Gao, Wenqiang Xu, Yanchun Zhang, Xueyang Jiang, Xiaodong Ma, Yang Wang

Bioorganic Chemistry · 2026

DOI: 10.1016/j.bioorg.2026.110243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Yulei Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Histone Deacetylase Inhibitors, Histone Deacetylases, Antineoplastic Agents. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Department of Education of Anhui Province, National Natural Science Foundation of China, Anhui University of Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The concurrent inhibition of oncogenic STAT3 and HDAC is a feasible avenue to achieving synergism and delaying drug resistance. Tyr705 and Ser727 serve as the two phosphorylation sites critical for manipulating the biological function of STAT3. Despite their complementary role in tumorigenesis, STAT3/HDAC bifunctional inhibitors simultaneously blocking Tyr705 and Ser727 phosphorylation have not been documented. Herein, SH-17 has been identified as a pioneering STAT3/HDAC bifunctional inhibitor impairing STAT3 phosphorylation at both Tyr705 and Ser727. It exhibited submicromolar or low micromolar IC50 values (0.411-4.85 μM) against various STAT3-aberrant malignant cells. With a binding affinity of 0.87 μM to STAT3 in SPR assay, SH-17 also potently inhibited the biochemical activity of representative HDACs. In cancer cells, it dramatically impaired STAT3 phosphorylation at both Tyr705 and Ser727 and suppressed deacetylation of HDAC substrates at low micromolar concentration. SH-17 was capable of obstructing intracellular ATP production and mitochondrial OXPHOS. Besides, it induced cell cycle arrest at G0/G1 phase and apoptosis at submicromolar concentration. In addition to its in vitro performance, SH-17 demonstrated acceptable in vivo PK parameters following intraperitoneal administration, thereby deserving further optimization as a STAT3/HDAC bifunctional inhibitor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorHistone Deacetylase InhibitorsHistone DeacetylasesAntineoplastic AgentsDrug DiscoveryPhosphorylationHumansAnimalsDose-Response Relationship, DrugMolecular StructureStructure-Activity RelationshipApoptosisCell ProliferationDrug Screening Assays, AntitumorTyrosineSerine

Stichwörter der Autor:innen

Anti-cancerBifunctional inhibitorHDACSTAT3Tyr705 and Ser727 phosphorylation

Substanzen

STAT3 Transcription FactorHistone Deacetylase InhibitorsHistone DeacetylasesSTAT3 protein, humanAntineoplastic AgentsTyrosineSerine

Autor:innen und Institutionen

  • College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
  • College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China; Institute of Medicinal Chemistry, Anhui Academy of Chinese Medicine, Hefei 230012, China.
  • College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China; Institute of Medicinal Chemistry, Anhui Academy of Chinese Medicine, Hefei 230012, China. Electronic address: jiang0568@126.com.
  • College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China; Institute of Medicinal Chemistry, Anhui Academy of Chinese Medicine, Hefei 230012, China; Anhui Province Key Laboratory of Bioactive Natura…
  • College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China; Institute of Medicinal Chemistry, Anhui Academy of Chinese Medicine, Hefei 230012, China. Electronic address: wangyang1991@ahtcm.edu.cn.

Förderung

  • Department of Education of Anhui Province
  • National Natural Science Foundation of China
  • Anhui University of Chinese Medicine

Zitieren

APA

Liu, Y., Gao, X., Xu, W., Zhang, Y., Jiang, X., Ma, X., & Wang, Y. (2026). Discovery of SH-17 as a pioneering STAT3/HDAC bifunctional inhibitor that simultaneously impairs Tyr705 and Ser727 phosphorylation. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110243

Vancouver

Liu Y, Gao X, Xu W, Zhang Y, Jiang X, Ma X, et al. Discovery of SH-17 as a pioneering STAT3/HDAC bifunctional inhibitor that simultaneously impairs Tyr705 and Ser727 phosphorylation. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110243

BibTeX
@article{Liu2026,
  author = {Liu, Yulei and Gao, Xiuxiu and Xu, Wenqiang and Zhang, Yanchun and Jiang, Xueyang and Ma, Xiaodong and Wang, Yang},
  title = {Discovery of SH-17 as a pioneering STAT3/HDAC bifunctional inhibitor that simultaneously impairs Tyr705 and Ser727 phosphorylation},
  journal = {Bioorganic Chemistry},
  year = {2026},
  doi = {10.1016/j.bioorg.2026.110243}
}
Kostenlos starten →